Fenoldopamum [Latin]
Fenoldopamum [Latin] Brand names, Fenoldopamum [Latin] Analogs
Fenoldopamum [Latin] Brand Names Mixture
- No information avaliable
Fenoldopamum [Latin] Chemical_Formula
C20H32F2O5
Fenoldopamum [Latin] RX_link
No information avaliable
Fenoldopamum [Latin] fda sheet
Fenoldopamum [Latin] msds (material safety sheet)
Fenoldopamum [Latin] Synthesis Reference
No information avaliable
Fenoldopamum [Latin] Molecular Weight
390.462 g/mol
Fenoldopamum [Latin] Melting Point
No information avaliable
Fenoldopamum [Latin] H2O Solubility
Practically insoluble
Fenoldopamum [Latin] State
Solid
Fenoldopamum [Latin] LogP
4.453
Fenoldopamum [Latin] Dosage Forms
Capsule (24 µg)
Fenoldopamum [Latin] Indication
For the treatment of chronic idiopathic constipation in the adult population.
Fenoldopamum [Latin] Pharmacology
Chronic idiopathic constipation is generally defined by infrequent or difficult passage of stool. The signs and symptoms associated with chronic idiopathic constipation (i.e., abdominal pain or discomfort, bloating, straining, and hard or lumpy stools) may be the result of abnormal colonic motility that can delay the transit of intestinal contents and impede the evacuation of rectal contents. One approach to the treatment of chronic idiopathic constipation is the secretion of fluid into the abdominal lumen through the activation of chloride channels in the apical membrane of the gastrointestinal epithelium. Lubiprostone is a locally acting chloride channel activator that enhances a chloride-rich intestinal fluid secretion without altering sodium and potassium concentrations in the serum.
Fenoldopamum [Latin] Absorption
Lubiprostone has low systemic availability following oral administration and concentrations of lubiprostone in plasma are below the level of quantitation (10 pg/mL).
Fenoldopamum [Latin] side effects and Toxicity
In a definitive Phase 1 cardiac repolarization study, 51 patients were administered a single oral dose of 144 mcg of lubiprostone, which is 6 times the normal single administration dose. Thirty-nine (39) of the 51 patients experienced an adverse event. The adverse events reported in >1% of this group included the following: nausea (45.1%), vomiting (27.5%), diarrhea (25.5%), dizziness (17.6%), loose or watery stools (13.7%), headache (11.8%), retching (7.8%), abdominal pain (5.9%), flushing or hot flush (5.9%), dyspnea (3.9%), pallor (3.9%), stomach discomfort (3.9%), syncope (3.9%), upper abdominal pain (2.0%), anorexia (2.0%), asthenia (2.0%), chest discomfort (2.0%), dry mouth (2.0%), hyperhidrosis (2.0%), skin irritation (2.0%) and vasovagal episode (2.0%).
Fenoldopamum [Latin] Patient Information
No information avaliable
Fenoldopamum [Latin] Organisms Affected
Humans and other mammals
